Yanan Li's research while affiliated with Shantou Central Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (2)
Objective
Intravenous tissue plasminogen activator (tPA) is the standard therapy for patients with acute ischaemic stroke (AIS) within 4.5 hours of onset. Recent trials have expanded the endovascular treatment window to 24 hours. We investigated the efficacy and safety of using multimodal MRI to guide intravenous tPA treatment for patients with AIS...
The aim of this study was to investigate the effect of lysosomal and ubiquitin-proteasome system dysfunction on the abnormal aggregation of α-synuclein, and to analyze its role in the pathogenesis of Parkinson's disease (PD). PC12 cells subjected to nerve growth factor-induced differentiation were used as the cell model to study the dopaminergic ne...
Citations
... Nowadays, numerous randomized controlled studies have shown that treatments such as intravenous thrombolysis, endovascular therapy and antiplatelet agents have good efficacy for AIS and can improve the clinical symptoms and prognosis of AIS patients. [3][4][5][6][7] However, post-stroke complications such as early neurological deterioration (END), stroke-associated pneumonia, symptomatic intracranial hemorrhage, and malignant cerebral edema can exacerbate symptoms, worsen the condition, and offset the benefits of clinical treatment. [8][9][10][11] Of these patients, 2.2% to 37.5% continue to have END after treatment, [12] and END has been shown to be associated with a poor prognosis in AIS. ...
... -E-64 didn't cause accumulation of endogenous monomeric or oligomeric α-synuclein in SH-SY5Y cells(122).-E-64 increased α-synuclein aggregate formation in differentiated PC12 cells(123) and in monkey fibroblasts induced to express human α-synuclein(90).by guest on November 23, 2020 http://www.jbc.org/ ...
![[object Object]](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
